Matinas BioPharma (MTNB) Tops Q2 EPS by 1c

Matinas BioPharma (NYSE: MTNB) reported Q2 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).

For earnings history and earnings-related data on Matinas BioPharma (MTNB) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• HII targets 15% shipbuilding throughput increase for U.S. Navy in 2026
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy